IL287802B2 - Compositions and methods for treatment of ocular diseases - Google Patents

Compositions and methods for treatment of ocular diseases

Info

Publication number
IL287802B2
IL287802B2 IL287802A IL28780221A IL287802B2 IL 287802 B2 IL287802 B2 IL 287802B2 IL 287802 A IL287802 A IL 287802A IL 28780221 A IL28780221 A IL 28780221A IL 287802 B2 IL287802 B2 IL 287802B2
Authority
IL
Israel
Prior art keywords
antibiotic
hydrogel
ocular composition
thiolated
concentration
Prior art date
Application number
IL287802A
Other languages
English (en)
Hebrew (he)
Other versions
IL287802B1 (en
IL287802A (en
Original Assignee
Eyegate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyegate Pharmaceuticals Inc filed Critical Eyegate Pharmaceuticals Inc
Publication of IL287802A publication Critical patent/IL287802A/en
Publication of IL287802B1 publication Critical patent/IL287802B1/en
Publication of IL287802B2 publication Critical patent/IL287802B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL287802A 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases IL287802B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842995P 2019-05-03 2019-05-03
PCT/US2020/030691 WO2020227002A1 (en) 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases

Publications (3)

Publication Number Publication Date
IL287802A IL287802A (en) 2022-01-01
IL287802B1 IL287802B1 (en) 2024-05-01
IL287802B2 true IL287802B2 (en) 2024-09-01

Family

ID=70861542

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287802A IL287802B2 (en) 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases

Country Status (9)

Country Link
US (2) US11376214B2 (https=)
EP (1) EP3962452A1 (https=)
JP (1) JP7334266B2 (https=)
KR (2) KR102649858B1 (https=)
CN (1) CN114025742A (https=)
CA (1) CA3139060A1 (https=)
IL (1) IL287802B2 (https=)
MX (1) MX2021013447A (https=)
WO (1) WO2020227002A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10945858B2 (en) * 2010-09-03 2021-03-16 Globus Medical, Inc. Expandable interspinous process fixation device
GB202008857D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
GB202008853D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
CN112587475B (zh) * 2020-12-18 2022-09-13 华熙生物科技股份有限公司 一种载药凝胶及其制备方法
DE102023116924A1 (de) * 2023-06-27 2025-01-02 Carl Zeiss Meditec Ag Kit zur Verwendung in einer Augenoperation und ophthalmische viskoelastische Vorrichtung
WO2025155730A1 (en) * 2024-01-16 2025-07-24 Regents Of The University Of Minnesota Injectable hydrogel for embolization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150157563A1 (en) * 2013-10-17 2015-06-11 Jade Therapeutics, Inc Ocular composition and method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312076T1 (de) * 2001-02-22 2005-12-15 Anika Therapeutics Inc Thiol-modifizierte hyaluronan-derivate
CA2703807C (en) * 2010-05-12 2017-10-24 Molly S. Shoichet Enhanced stability of inverse thermal gelling composite hydrogels
US10137199B2 (en) * 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
EP3675873A4 (en) * 2017-09-01 2021-06-16 Pmidg, Llc Functionalized and crosslinked polymers
US12029753B2 (en) * 2017-09-19 2024-07-09 The Hong Kong University Of Science And Technology Biocompatible material and methods for making and using thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150157563A1 (en) * 2013-10-17 2015-06-11 Jade Therapeutics, Inc Ocular composition and method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARBARA WIROSTKO ET AL.:, OPHTHALMIC USES OF A THIOL-MODIFIED HYALURONAN-BASED HYDROGEL, 4 November 2014 (2014-11-04) *
SHIRLEY LUO ET AL.:, HYALURONAN-BASED SUSTAINED DELIVERY OF THE ANTIBIOTIC BESIFLOXACIN TO THE EYE, 9 April 2016 (2016-04-09) *
YANG G. ET AL.: THIOLATED CARBOXYMETHYL-HYALURONIC-ACID-BASED BIOMATERIALS ENHANCE WOUND HEALING IN RATS, DOGS, AND HORSES, THIOLATED CARBOXYMETHYL-HYALURONIC-ACID-BASED BIOMATERIALS ENHANCE WOUND HEALING IN RATS, DOGS, AND HORSES, 11 January 2012 (2012-01-11) *

Also Published As

Publication number Publication date
IL287802B1 (en) 2024-05-01
MX2021013447A (es) 2022-02-11
KR20220004753A (ko) 2022-01-11
WO2020227002A1 (en) 2020-11-12
CA3139060A1 (en) 2020-11-12
JP7334266B2 (ja) 2023-08-28
IL287802A (en) 2022-01-01
CN114025742A (zh) 2022-02-08
US20200345634A1 (en) 2020-11-05
US11376214B2 (en) 2022-07-05
KR20240038152A (ko) 2024-03-22
JP2022530837A (ja) 2022-07-01
EP3962452A1 (en) 2022-03-09
US20220287961A1 (en) 2022-09-15
KR102649858B1 (ko) 2024-03-20

Similar Documents

Publication Publication Date Title
US20220287961A1 (en) Compositions and methods for treatment of ocular diseases
CN107847604B (zh) 眼用原位凝胶处方
EP2785328B1 (en) Novel slow-releasing ophthalmic compositions comprising povidone iodine
Dubey et al. Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma
Alase Sustained ophthalmic delivery of gatifloxacin from in situ gelling system
AU2014293665A1 (en) Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent
JP6941157B2 (ja) 眼科用組成物
US20210290527A1 (en) Compositions and Methods for Treatment of Ocular Conditions
EP4260844B1 (en) Ophthalmological compositions comprising poloxamer
US20120101056A1 (en) Medicinal Cream Made Using Framycetin Sulphate and Chitosan and a Process to Make the Same
US9814673B2 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
CN119326771A (zh) 包含泊洛沙姆的眼科组合物
HK40105104A (en) Ophthalmological compositions comprising poloxamer
CN118121709A (zh) 一种眼用药物组合物及其制备方法、应用
HK1248100B (zh) 眼用原位凝胶处方
Khan Formulation and Evaluation of Controlled Release Ocular Inserts of Erythromycin